Home · Research · Longevity & bioregulators

Vesilute research

What published studies found for Vesilute: 1 paper, 0 in humans, with sample sizes and key results.

Little or no evidence

Why: Only one in-vitro study of human thymus cells from the developer's institute; no animal or human studies.

Vesilute (the dipeptide Gly-Asp, a Khavinson bioregulator) has almost no indexed research: one Russian in-vitro paper from the developer's institute reports effects on human thymus cells, and no human trial of vesilute itself was found. The bladder-peptide trials found under other names could not be attributed to vesilute and were not used.

✓ 1 positive

No safety data for vesilute in the published literature found.

US compounding: Not compoundable. Not an FDA-approved drug and not nominated for FDA's 503A bulks list, so US pharmacies can't legally compound it. Status for every peptide.

Browse and filter these papers Vesilute prices and vendors

Animal & lab studies

✓ Positivein vitroКлиническая геронтология · 2010Russian-language

Сравнительное действие везугена и везилюта на восстановление функций тимуса при его старении

Cells / labIn vitro comparison of vesugen (Lys-Glu-Asp) and vesilute (Gly-Asp); a separate rat experiment tested vesugen only

In cultured human thymus cells, vesilute (Gly-Asp) and vesugen increased CD54 and HLA-DR expression on thymocytes, reduced their apoptosis and raised cytokine secretion by thymic epithelial cells; developer's institute, abstract gives no numbers or controls.

Studied: Human thymus cells (thymocytes and thymic epithelial cells) in culture
Main outcome: Activation antigens (CD54, HLA-DR), apoptosis and cytokine secretion
Authors' conclusion: Both peptides showed marked immunogeroprotective properties in human thymus cells in vitro: they raised CD54 and HLA-DR expression, weakened thymocyte apoptosis and enhanced cytokine secretion by thymic epithelial cells.
Limitations: In vitro only for vesilute; no numbers in the text available; authors from the developer's institute.

CyberLeninka (Russian)

Verdicts are judged on each paper's own main outcome; grades run from A (strong human evidence) to D (little or none). Details are read from the abstracts, and figures are reproduced only from openly licensed full texts. Not medical advice.